Quantcast
Last updated on April 16, 2014 at 5:31 EDT

Latest Peptides Stories

2013-05-21 04:20:51

SALT LAKE CITY, May 21, 2013 /PRNewswire/ -- MAX International, L.L.C. (www.max.com/chuck) announces that Chuck Norris and his wife Gena Norris will serve as media campaign spokespersons and worldwide ambassadors for the company's health and sports nutraceutical products. (Photo: http://photos.prnewswire.com/prnh/20130521/FL13779-a)(Logo: http://photos.prnewswire.com/prnh/20130521/FL13779LOGO-b) Available in eight countries, MAX's patented nutrients and nutritional products were...

2013-05-07 16:28:18

Penn State College of Medicine researchers state that oral supplementation can increase the body's stores of the powerful antioxidant, Glutathione. NEW YORK, May 7, 2013 /PRNewswire-iReach/ -- Glutathione is the body's master antioxidant involved in protecting cells and tissues from oxidants and a large variety of other toxins and insults. Debate over whether orally administered glutathione could be effective at enhancing glutathione levels in cells and tissues has simmered for...

2013-03-25 04:22:24

LUND, Sweden, March 25, 2013 /PRNewswire/ -- NeuroVive, a leading mitochondrial medicine company, announces that its shares have been approved for listing on NASDAQ OMX Stockholm by the exchange's Listing Committee. The first day of trading on NASDAQ OMX Stockholm will be April 10th and the last day of trading on the Swedish trading platform AktieTorget will be April 9th. The stock will be traded under the same ticker symbol, NVP. No new shares will be issued in...

2013-03-22 08:24:26

LUND, Sweden, March 22, 2013 /PRNewswire/ -- NeuroVive, a leading mitochondrial medicine company, announces that the 600th patient has been recruited to a pivotal Phase III European, multi-center trial (CIRCUS trial) assessing CicloMulsion(R) (a special formulation of cyclosporine for acute cardiac injuries) for the treatment of heart reperfusion injury following stenting in patients with myocardial infarction. The CIRCUS trial (does Cyclosporine ImpRove Clinical oUtcome...

2013-03-11 08:26:46

LUND, Sweden, March 11, 2013 /PRNewswire/ -- NeuroVive, a leading mitochondrial medicine company, announces it has completed the acquisition of a portfolio of novel cyclophilin inhibitors, technology platform assets and related intellectual property rights from the UK biotech company Biotica Ltd. The acquisition of these assets is important strategically as it will allow NeuroVive to broaden and deepen its pipeline of novel mitochondrial medicines. No financial details of the...

2013-02-18 08:23:10

BASEL, Switzerland, NEW YORK and JERUSALEM, Feb. 18, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Chiasma (pronounced key-az-ma) Inc., a privately held biopharma company, announced today that they have entered into an agreement to develop and commercialize Chiasma's proprietary product Octreolin, initially for acromegaly and subsequently for neuroendocrine tumors. Octreolin is an investigational oral form of the peptide octreotide, a somatostatin analog that is...

2013-01-18 12:22:32

TAMPA, Fla., Jan. 18, 2013 /PRNewswire-iReach/ -- One of the most popular and powerful products offered by US Vitamin Injections is the anti-oxidant glutathione. Glutathione is an anti-oxidant that is contained within our bodies and acts as a buffer for any harmful toxins, chemicals or damaged cells that are introduced. Luckily the body is capable of producing its own glutathione which keeps the body healthy and functioning properly. (Photo:...

2013-01-10 05:04:28

LifeWave compiled an up-to-date list of the top anti-aging products on the market today with a brief description of their benefits and costs. The #1 aging product might be surprising to you. Monero Valley, CA (PRWEB) January 09, 2013 Everyone is concerned about how fast they will age. Recently, the top anti-aging products have been compiled into a condensed list for consumer use. The number one solution on the list is the new natural supplement, glutathione. Glutathione is considered the...

2012-12-19 08:25:55

BASKING RIDGE, N.J., Dec. 19, 2012 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced it has secured a landmark $51 million Series E financing. The round was led by new investor RusnanoMedInvest, a subsidiary of the state-run Russian investment firm RUSNANO, and included participation from another new, US-based investor, Baxter Healthcare's venture initiative, Baxter Ventures. Existing...

2012-12-05 12:24:29

BASKING RIDGE, N.J., Dec. 5, 2012 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the Oppenheimer 23(rd) Annual Healthcare Conference at 11:10 a.m. ET on Wednesday, December 12, 2012 in the Louis XVI Room at the Waldorf Astoria in New York City. The presentation will include an overview of the Company's...